Related Experiment Videos
Current update of adoptive immunotherapy using cytokine-induced killer cells to eliminate malignant gliomas
Je Il Ryu1, Myung Hoon Han1, Jin Hwan Cheong1
1Department of Neurosurgery, Hanyang University Guri Hospital, 153 Gyeongchun-ro, Guri 471-701, Gyonggi-do, Republic of Korea.
Abstract:
The therapeutic outcome for those with malignant glioma is poor, even though diverse therapeutic modalities have been developed. Immunotherapy has emerged as a therapeutic approach for malignant gliomas, making it possible to selectively treat tumors while sparing normal tissue. Here, we review clinical trials of adoptive immunotherapy approaches for malignant gliomas. We also describe a clinical trial that examined the efficacy and safety of autologous cytokine-induced killer (CIK) cells along with concomitant chemoradiotherapy for newly diagnosed glioblastoma. These CIK cells identify and kill autologous tumor cells. This review focuses on the use of adoptive immunotherapy for malignant gliomas and reviews the current literature on the concept of antitumor activity mediated by CIK cells.
Insights
Adoptive immunotherapy using cytokine-induced killer (CIK) cells shows promise for treating malignant gliomas. This approach selectively targets tumors, offering a potential new avenue for patients with poor therapeutic outcomes.
Area of Science:
- Neuro-oncology
- Immunology
- Cancer Therapy
Background:
- Malignant gliomas have a poor therapeutic outcome despite various treatment modalities.
- Immunotherapy offers selective tumor treatment, sparing healthy tissues.
- Adoptive immunotherapy is an emerging strategy for malignant gliomas.
Purpose of the Study:
- To review clinical trials of adoptive immunotherapy for malignant gliomas.
- To describe a clinical trial investigating autologous cytokine-induced killer (CIK) cells with chemoradiotherapy for glioblastoma.
- To focus on the antitumor activity of CIK cells in malignant gliomas.
Main Methods:
- Review of clinical trials on adoptive immunotherapy for malignant gliomas.
- Description of a clinical trial using autologous CIK cells and chemoradiotherapy for newly diagnosed glioblastoma.
- Analysis of literature on CIK cell-mediated antitumor activity.
Main Results:
- Autologous CIK cells can identify and kill autologous tumor cells.
- Concomitant chemoradiotherapy with CIK cells was examined for efficacy and safety.
- The review synthesizes current literature on CIK cell immunotherapy for gliomas.
Conclusions:
- Adoptive immunotherapy, particularly with CIK cells, presents a potential therapeutic option for malignant gliomas.
- CIK cells demonstrate antitumor activity relevant to glioma treatment.
- Further research and clinical trials are warranted to establish the role of CIK cells in glioma therapy.